

Trying 3106016892...Open

Welcome to STN International! Enter x:x

LOGINID:sssptal202txn

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Sep 29	The Philippines Inventory of Chemicals and Chemical Substances (PICCS) has been added to CHEMLIST
NEWS	3	Oct 27	New Extraction Code PAX now available in Derwent Files
NEWS	4	Oct 27	SET ABBREVIATIONS and SET PLURALS extended in Derwent World Patents Index files
NEWS	5	Oct 27	Patent Assignee Code Dictionary now available in Derwent Patent Files
NEWS	6	Oct 27	Plasdoc Key Serials Dictionary and Echoing added to Derwent Subscriber Files WPIDS and WPIX
NEWS	7	Nov 29	Derwent announces further increase in updates for DWPI
NEWS	8	Dec 5	French Multi-Disciplinary Database PASCAL Now on STN
NEWS	9	Dec 5	Trademarks on STN - New DEMAS and EUMAS Files
NEWS	10	Dec 15	2001 STN Pricing
NEWS	11	Dec 17	Merged CEABA-VTB for chemical engineering and biotechnology
NEWS	12	Dec 17	Corrosion Abstracts on STN
NEWS	13	Dec 17	SYNTHLINE from Prous Science now available on STN
NEWS	14	Dec 17	The CA Lexicon available in the CAPLUS and CA files
NEWS	15	Jan 05	AIDSLINE is being removed from STN
NEWS EXPRESS			FREE UPGRADE 5.0e FOR STN EXPRESS 5.0 WITH DISCOVER! (WINDOWS) NOW AVAILABLE
NEWS HOURS			STN Operating Hours Plus Help Desk Availability
NEWS INTER			General Internet Information
NEWS LOGIN			Welcome Banner and News Items
NEWS PHONE			Direct Dial and Telecommunication Network Access to STN
NEWS WWW			CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 10:05:32 ON 09 JAN 2001

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

09/ 582,442

	ENTRY	SESSION
FULL ESTIMATED COST	0.15	0.15

FILE 'REGISTRY' ENTERED AT 10:05:38 ON 09 JAN 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 8 JAN 2001 HIGHEST RN 313216-31-8
DICTIONARY FILE UPDATES: 8 JAN 2001 HIGHEST RN 313216-31-8

TSCA INFORMATION NOW CURRENT THROUGH July 8, 2000

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT
for details.

=>


Uploading 582442.str

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



G1 CH2, SO2

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 10:06:14 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 245 TO ITERATE

100.0% PROCESSED	245 ITERATIONS	18 ANSWERS
SEARCH TIME: 00.00.01		


FULL FILE PROJECTIONS:	ONLINE	**COMPLETE**
	BATCH	**COMPLETE**
PROJECTED ITERATIONS:	3961 TO	5839
PROJECTED ANSWERS:	106 TO	614

L2 18 SEA SSS SAM L1

=> d scan 12

L2 18 ANSWERS REGISTRY COPYRIGHT 2001 ACS
 IN Piperazinone, 4-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monohydrochloride (9CI)
 MF C23 H27 Cl N4 O3 S . Cl H

Double bond geometry as shown.



● HCl

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s 11 ful

FULL SEARCH INITIATED 10:06:40 FILE 'REGISTRY'
 FULL SCREEN SEARCH COMPLETED - 4494 TO ITERATE

100.0% PROCESSED 4494 ITERATIONS
 SEARCH TIME: 00.00.04

375 ANSWERS

L3 375 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
133.87	134.02

FULL ESTIMATED COST

FILE 'CAPLUS' ENTERED AT 10:06:53 ON 09 JAN 2001
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1967 - 9 Jan 2001 VOL 134 ISS 3
 FILE LAST UPDATED: 8 Jan 2001 (20010108/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REGISTRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

Now you can extend your author, patent assignee, patent information, and title searches back to 1907. The records from 1907-1966 now have this searchable data in CAOLD. You now have electronic access to all of CA: 1907 to 1966 in CAOLD and 1967 to the present in CAPLUS on STN.

The CA Lexicon is now available in the Controlled Term (/CT) field. Enter HELP LEXICON for full details.

Attention, the CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

=> s 13

L4 8 L3

=> d 14 1- ibib abs hitstr

YOU HAVE REQUESTED DATA FROM 8 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2001 ACS
 ACCESSION NUMBER: 1999:511143 CAPLUS
 DOCUMENT NUMBER: 131:170361
 TITLE: Preparation of sulfonamides as inhibitors of
 activated
 blood coagulation factor X
 INVENTOR(S): Tawada, Hiroyuki; Itoh, Fumio; Banno, Hiroshi;
 Terashita, Zenichi
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
 SOURCE: PCT Int. Appl., 187 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9940075	A1	19990812	WO 1999-JP470	19990204
W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GD, GE, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA, US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				

RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG


AU 9922988	A1	19990823	AU 1999-22988	19990204
JP 2000204081	A2	20000725	JP 1999-27053	19990204
EP 1054005	A1	20001122	EP 1999-902829	19990204

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI

PRIORITY APPLN. INFO.: JP 1998-24833 19980205
JP 1998-317205 19981109
WO 1999-JP470 19990204

OTHER SOURCE(S): MARPAT 131:170361

GI



AB The title compds. I [R¹ represents a hydrocarbonyl or heterocyclic group each optionally substituted; the ring A represents a divalent nitrogen-contg. heterocycle group optionally further substituted; X' represents optionally substituted alkylene; Y represents an optionally substituted divalent cyclic group; X represents a bond or optionally substituted alkylene; and Z represents optionally substituted amino, optionally substituted imido, or an optionally substituted nitrogen-contg. heterocyclic group] are prepd. Formulations contg. a compd. of this invention are given. In a test for inhibiting activity of title compds. against activated blood coagulation factor X, 1-(4-amidinobenzyl)-4-(6-chloronaphthalene-2-sulfonyl)-2-piperazinone hydrochloride showed IC₅₀ of 0.05 .mu.M.

IT 229646-37-1P 239071-44-4P 239071-46-6P
239071-47-7P 239071-48-8P 239071-50-2P
239071-51-3P 239071-52-4P 239071-53-5P
239071-54-6P 239071-55-7P 239071-62-6P
239071-63-7P 239071-64-8P 239071-65-9P
239071-66-0P 239071-67-1P 239071-68-2P
239071-69-3P 239071-70-6P 239071-71-7P
239071-79-5P 239071-81-9P 239071-82-0P
239071-83-1P 239071-85-3P 239071-86-4P
239071-87-5P 239071-88-6P 239071-92-2P
239071-93-3P 239071-94-4P 239071-97-7P
239071-98-8P 239071-99-9P 239072-00-5P
239072-01-6P 239072-02-7P 239072-03-8P
239072-05-0P 239072-23-2P 239072-29-8P
239072-30-1P 239072-31-2P 239072-32-3P
239072-33-4P 239072-34-5P 239072-35-6P
239072-36-7P 239072-37-8P 239072-38-9P
239072-39-0P 239072-40-3P 239072-41-4P
239072-42-5P 239072-43-6P 239072-44-7P
239072-45-8P 239072-46-9P 239072-47-0P
239072-48-1P 239072-49-2P 239072-50-5P

239072-51-6P 239072-52-7P 239072-53-8P

239072-54-9P 239072-57-2P 239072-58-3P

239072-60-7P 239072-62-9P 239072-63-0P

239072-64-1P 239072-65-2P 239072-66-3P

239072-67-4P 239072-68-5P 239072-69-6P

239074-62-5P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of sulfonamides as inhibitors of activated blood coagulation factor X)

RN 229646-37-1 CAPLUS

CN Piperazinone,


4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 239071-44-4 CAPLUS

CN Piperazinone,

4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 239071-46-6 CAPLUS

CN Piperazinone, 4-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Double bond geometry as shown.



● HCl

RN 239071-47-7 CAPLUS


CN Piperazinone, 4-[(4-ethenylphenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 239071-48-8 CAPLUS

CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[[4-hydroxy-1-(4-pyridinyl)-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 239071-50-2 CAPLUS

CN Piperazinone, 4-[(4-ethenylphenyl)sulfonyl]-1-[[4-hydroxy-1-(4-pyridinyl)-


4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)



RN 239071-51-3 CAPLUS

CN Piperazinone,

4-[(4-ethenylphenyl)sulfonyl]-1-[[4-hydroxy-1-(4-pyridinyl)-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 239071-52-4 CAPLUS


CN Piperazinone,

4-[(7-chloro-2H-1-benzopyran-3-yl)sulfonyl]-1-[[4-hydroxy-1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 239071-53-5 CAPLUS

CN Piperazinone, 1-[[4-(acetyloxy)-1-(4-pyridinyl)-4-piperidinyl]methyl]-4-[(6-chloro-2-naphthalenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 239071-54-6 CAPLUS

CN Piperazinone, 1-[[4-(acetyloxy)-1-(4-pyridinyl)-4-piperidinyl]methyl]-4-[(4-ethenylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 239071-55-7 CAPLUS

CN Piperazinone, 1-[[4-(acetyloxy)-1-(4-pyridinyl)-4-piperidinyl]methyl]-4-[(7-chloro-2H-1-benzopyran-3-yl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 239071-62-6 CAPLUS


CN 4-Piperidinecarboxylic acid, 4-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-1-piperazinyl]methyl]-1-(4-pyridinyl)-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 239071-63-7 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-[[4-[(7-chloro-2H-1-benzopyran-3-yl)sulfonyl]-2-oxo-1-piperazinyl]methyl]-1-(4-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)




RN 239071-64-8 CAPLUS

CN Piperazinone,
4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[[4-(hydroxymethyl)-1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 239071-65-9 CAPLUS


CN 4-Piperidinecarboxylic acid, 4-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-1-piperazinyl]methyl]-1-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 239071-66-0 CAPLUS
 CN 4-Piperidinecarboxamide,
 4-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-1-
 piperazinyl]methyl]-N,N-dimethyl-1-(4-pyridinyl)- (9CI) (CA INDEX NAME)



RN 239071-67-1 CAPLUS
 CN 4-Piperidinecarboxamide,
 4-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-1-
 piperazinyl]methyl]-N-methyl-1-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 239071-68-2 CAPLUS
 CN 4-Piperidinecarboxamide,
 4-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-1-
 piperazinyl]methyl]-1-(4-pyridinyl)- (9CI) (CA INDEX NAME)




RN 239071-69-3 CAPLUS

RXN
 CN
 Piperazinone, 4-[[6-chloro-2-naphthalenyl)sulfonyl]-1-[[4-hydroxy-1-(1-oxido-4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 239071-70-6 CAPLUS

4-Piperidinecarboxylic acid, 4-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-1-piperazinyl)methyl]-1-(1-oxido-4-pyridinyl)-, methyl ester (9CI)
(CA INDEX NAME)




RN 239071-71-7 CAPLUS

1-Piperazineacetonitrile, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-
.alpha.-[1-(4-pyridinyl)-4-piperidinyl]- (9CI) (CA INDEX NAME)



RN 239071-79-5 CAPLUS


CN Piperazinone, 4-[(7-chloro-2H-1-benzopyran-3-yl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 239071-81-9 CAPLUS


CN Piperazinone, 4-[(5-chloro-2-benzofuranyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 239071-82-0 CAPLUS

CN Piperazinone, 4-[[5-(4-chlorophenyl)-2-thienyl]sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 239071-83-1 CAPLUS


CN Piperazinone, 4-[(5-ethenyl-2-thienyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 239071-85-3 CAPLUS

CN Piperazinone, 4-[(6-chloro-3,4-dihydro-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 239071-86-4 CAPLUS

CN Piperazinone, 4-[(6-bromo-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 239071-87-5 CAPLUS

CN Piperazinone,

4-[(6-fluoro-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 239071-88-6 CAPLUS

CN Piperazinone,


4-[(6-methyl-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 239071-92-2 CAPLUS


CN: Piperazinone, 4-[(7-bromo-2H-1-benzopyran-3-yl)sulfonyl]-1-[[4-hydroxy-1-(4-pyridinyl)-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 239071-93-3 CAPLUS


CN: Piperazinone, 4-[(7-chloro-6-fluoro-2H-1-benzopyran-3-yl)sulfonyl]-1-[[4-hydroxy-1-(4-pyridinyl)-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



HCl


RN 239071-94-4 CAPLUS

CN Piperazinone,

4-[(7-chloro-4-hydroxy-2-oxo-2H-1-benzopyran-3-yl)sulfonyl]-
1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)


RN 239071-97-7 CAPLUS

CN Piperazinone, 4-[(7-chloro-2-oxo-2H-1-benzopyran-3-yl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 239071-98-8 CAPLUS

CN 1-Piperazinepropanoic acid, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-.beta.-[1-(4-pyridinyl)-4-piperidinyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 239071-99-9 CAPLUS

CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[[4-hydroxy-1-(4-pyrimidinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 239072-00-5 CAPLUS

CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[[1-(6-chloro-4-pyrimidinyl)-4-hydroxy-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 239072-01-6 CAPLUS

CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[[1-(2-chloro-4-pyrimidinyl)-4-hydroxy-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 239072-02-7 CAPLUS

CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[[4-hydroxy-1-[6-[(phenylmethyl)amino]-4-pyrimidinyl]-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 239072-03-8 CAPLUS


CN Piperazinone, 4-[[4-(4-ethenylphenyl)sulfonyl]-1-[[4-hydroxy-1-(4-pyrimidinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 239072-05-0 CAPLUS

CN Piperazinone, 4-[[4-(1H-imidazol-1-ylmethyl)phenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, dihydrochloride (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A




● 2 HCl

RN 239072-23-2 CAPLUS
 CN Piperazinone,
 4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[2-[1-(4-pyridinyl)-
 4-piperidinyl]ethyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 239072-29-8 CAPLUS
 CN Piperazinone,
 4-[[4-(1-methylethenyl)phenyl]sulfonyl]-1-[[1-(4-pyridinyl)-
 4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 239072-30-1 CAPLUS
 CN Piperazinone,
 4-[[4-(1-methylethenyl)phenyl]sulfonyl]-1-[[1-(4-pyridinyl)-
 4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 239072-31-2 CAPLUS
 CN Piperazinone,
 4-[[4-(1E)-1-propenylphenyl]sulfonyl]-1-[[1-(4-pyridinyl)-4-
 piperidinyl]methyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 239072-32-3 CAPLUS

CN Piperazinone, 4-[[4-(1E)-1-propenylphenyl]sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Double bond geometry as shown.



● HCl


RN 239072-33-4 CAPLUS

CN Piperazinone, 4-[(4-iodophenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 239072-34-5 CAPLUS


CN Piperazinone, 4-[(4-iodophenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 239072-35-6 CAPLUS

CN Piperazinone, 4-[(3-bromophenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 239072-36-7 CAPLUS


CN Piperazinone, 4-[(3-bromophenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 239072-37-8 CAPLUS


CN Piperazinone,
4-[(2-oxo-2H-1-benzopyran-6-yl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 239072-38-9 CAPLUS

CN Piperazinone,


4-[(2-oxo-2H-1-benzopyran-6-yl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 239072-39-0 CAPLUS

CN Piperazinone, 4-[(7-chloro-4-oxo-4H-1-benzopyran-3-yl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 239072-40-3 CAPLUS


CN Piperazinone, 4-[(7-chloro-4-oxo-4H-1-benzopyran-3-yl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 239072-41-4 CAPLUS

CN Piperazinone, 4-([1,1'-biphenyl]-4-ylsulfonyl)-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 239072-42-5 CAPLUS


CN Piperazinone, 4-([1,1'-biphenyl]-4-ylsulfonyl)-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 239072-43-6 CAPLUS

CN Piperazinone, 4-([1,1'-biphenyl]-3-ylsulfonyl)-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 239072-44-7 CAPLUS
 CN Piperazinone, 4-[(3'-chloro[1,1'-biphenyl]-3-yl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 239072-45-8 CAPLUS
 CN Piperazinone, 4-[(4-ethynylphenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 239072-46-9 CAPLUS
 CN Piperazinone, 4-[(4-ethynylphenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)




● HCl

RN 239072-47-0 CAPLUS
 CN Piperazinone, 4-[(3-ethynylphenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 239072-48-1 CAPLUS
 CN Piperazinone, 4-[(3-ethynylphenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 239072-49-2 CAPLUS
 CN Piperazinone, 4-[[4-[(1E)-2-chloroethenyl]phenyl]sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 239072-50-5 CAPLUS

CN Piperazinone, 4-[[4-[(1E)-2-chloroethenyl]phenyl]sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)


Double bond geometry as shown.



● HCl


RN 239072-51-6 CAPLUS

CN Piperazinone, 4-[(4-ethylphenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 239072-52-7 CAPLUS


CN Piperazinone, 4-[(4-ethylphenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 239072-53-8 CAPLUS

CN Piperazinone, 4-[(3-ethenylphenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 239072-54-9 CAPLUS


CN Piperazinone, 4-[(3-ethenylphenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 239072-57-2 CAPLUS

CN Piperazinone, 4-[(7-chloro-2H-1-benzopyran-3-yl)sulfonyl]-1-[[4-(1-oxopropoxy)-1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 239072-58-3 CAPLUS

CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[[4-methoxy-1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 239072-60-7 CAPLUS

CN Methanesulfonamide, N-[4-[[4-[(7-chloro-2H-1-benzopyran-3-yl)sulfonyl]-2-oxo-1-piperazinyl]methyl]-1-(4-pyridinyl)-4-piperidinyl]- (9CI) (CA

INDEX
NAME)


RN 239072-62-9 CAPLUS

CN Glycine, N-[[4-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-1-piperazinyl]methyl]-1-(4-pyridinyl)-4-piperidinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 239072-63-0 CAPLUS


CN Glycine, N-[[4-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-1-piperazinyl]methyl]-1-(4-pyridinyl)-4-piperidinyl]carbonyl]-, ethyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 239072-64-1 CAPLUS

CN .beta.-Alanine, N-[[4-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-1-piperazinyl]methyl]-1-(4-pyridinyl)-4-piperidinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 239072-65-2 CAPLUS

CN Butanoic acid, 4-[[[4-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-1-piperazinyl]methyl]-1-(4-pyridinyl)-4-piperidinyl]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX NAME)




RN 239072-66-3 CAPLUS

CN Glycine, N-[[4-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-1-piperazinyl]methyl]-1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 239072-67-4 CAPLUS

CN .beta.-Alanine, N-[[4-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-1-piperazinyl]methyl]-1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 239072-68-5 CAPLUS

CN Butanoic acid, 4-[[[4-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-1-piperazinyl]methyl]-1-(4-pyridinyl)-4-piperidinyl]carbonyl]amino]- (9CI) (CA INDEX NAME)




RN 239072-69-6 CAPLUS

CN Carbamic acid, [4-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-1-piperazinyl]methyl]-1-(4-pyridinyl)-4-piperidinyl]-, phenylmethyl ester (9CI) (CA INDEX NAME)



RN 239074-62-5 CAPLUS

CN Piperazinone, 4-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[[4-hydroxy-1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



IT 229646-35-9P 239073-05-3P 239073-27-9P

239073-28-0P 239073-46-2P 239073-50-8P


239073-69-9P 239074-19-2P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of sulfonamides as inhibitors of activated blood coagulation factor X)

RN 229646-35-9 CAPLUS


CN Piperazinone, 4-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 239073-05-3 CAPLUS

CN Piperazinone, 4-[(4-ethenylphenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 239073-27-9 CAPLUS

CN 4-Piperidinecarboxylic acid, 4-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-2-oxo-1-piperazinyl]methyl]-1-(4-pyridinyl)-, methyl ester (9CI) (CA INDEX NAME)



RN 239073-28-0 CAPLUS


CN 4-Piperidinecarboxylic acid, 4-[[4-[(7-chloro-2H-1-benzopyran-3-yl)sulfonyl]-2-oxo-1-piperazinyl]methyl]-1-(4-pyridinyl)-, methyl ester, monohydrochloride (9CI) (CA INDEX NAME)



● HCl


RN 239073-46-2 CAPLUS

CN Piperazinone, 4-[(7-chloro-2H-1-benzopyran-3-yl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 239073-50-8 CAPLUS


CN Piperazinone, 4-[(5-chloro-2-benzofuranyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 239073-69-9 CAPLUS

CN Piperazinone, 4-[[4-(1H-imidazol-1-ylmethyl)phenyl]sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

PAGE 1-A




PAGE 2-A



RN 239074-19-2 CAPLUS

CN Piperazinone,

4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[2-[1-(4-pyridinyl)-
4-piperidinyl]ethyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 15
 REFERENCE(S): (1) Takeda Chemical Industries Ltd; JP 09316059 A
 CAPLUS
 (2) Takeda Chemical Industries Ltd; CN 1069730 A
 CAPLUS
 (3) Takeda Chemical Industries Ltd; US 5294713 A
 CAPLUS
 (4) Takeda Chemical Industries Ltd; EP 529858 A1
 CAPLUS
 (5) Takeda Chemical Industries Ltd; EP 822931 A1
 CAPLUS
 ALL CITATIONS AVAILABLE IN THE RE FORMAT


L4 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2001 ACS
 ACCESSION NUMBER: 1999:460402 CAPLUS
 DOCUMENT NUMBER: 131:87833
 TITLE: Preparation of aromatic compounds having cyclic amino
 or salts thereof as FXa inhibitors
 INVENTOR(S): Nishida, Hidemitsu; Hosaka, Yoshitaka; Miyazaki,
 Yutaka; Matsusue, Tomokazu; Mukaihira, Takafumi
 PATENT ASSIGNEE(S): Mochida Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 218 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9933805	A1	19990708	WO 1998-JP6002	19981228
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
AU 9916923	A1	19990719	AU 1999-16923	19981228
EP 1048652	A1	20001102	EP 1998-961642	19981228
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
PRIORITY APPLN. INFO.:			JP 1997-367538	19971226

Applicant's

JP 1998-311491 19981030
WO 1998-JP6002 19981228

OTHER SOURCE(S): MARPAT 131:87833
GI



AB Title Compds. [I; G1, X and Y represent each CH or N; Z1 represents
-SO₂CH:CH- or -SO₂-; Q represents aryl or heteroaryl; and R₂ to R₉
represent each hydrogen or a substituent; n = 0-1] and salts thereof
which specifically inhibit FXa, exert a potent anticoagulant effect and thus
are useful as medicinal compns. are prepd. Title compd. I (G1 = N; X = N; Y
= CH; n = 0; R₂ = H; R₃ = H; R₄ = H; R₅ = H; R₆ = H; R₇ = H; R₈ = H; R₉ =
H; Z1 = (E)-SO₂CH:CH; Q = 4-ClC₆H₄) was prepd. in two steps.

IT 229646-14-4P 229646-15-5P 229646-16-6P
229646-17-7P 229646-18-8P 229646-19-9P
229646-20-2P 229646-21-3P 229646-22-4P
229646-23-5P 229646-24-6P 229646-25-7P
229646-26-8P 229646-27-9P 229646-28-0P
229646-29-1P 229646-30-4P 229646-32-6P
229646-33-7P 229646-34-8P 229646-35-9P
229646-36-0P 229646-37-1P 229646-38-2P
229646-39-3P 229646-40-6P 229646-41-7P
229646-42-8P 229646-43-9P 229646-44-0P
229646-45-1P 229646-46-2P 229646-47-3P
229646-48-4P 229646-49-5P 229646-50-8P
229646-51-9P 229646-52-0P 229646-53-1P
229646-54-2P 229646-55-3P 229646-56-4P
229646-57-5P 229646-58-6P 229646-59-7P
229646-60-0P 229646-61-1P 229646-62-2P
229646-63-3P 229646-64-4P 229646-65-5P
229646-66-6P 229646-67-7P 229646-68-8P
229646-69-9P 229646-70-2P 229646-71-3P
229646-72-4P 229646-73-5P 229646-74-6P
229646-75-7P 229646-76-8P 229646-77-9P
229646-78-0P 229646-79-1P 229646-80-4P
229646-81-5P 229646-82-6P 229646-83-7P
229646-84-8P 229646-85-9P 229646-86-0P
229646-87-1P 229646-88-2P 229646-89-3P
229646-90-6P 229646-91-7P 229646-92-8P
229646-93-9P 229646-94-0P 229646-95-1P


229646-96-2P 229646-97-3P 229646-98-4P
 229646-99-5P 229647-00-1P 229647-01-2P
 229647-02-3P 229647-03-4P 229647-04-5P
 229647-05-6P 229955-03-7P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (prepn. of arom. compds. having cyclic amino or salts thereof as FXa inhibitors)

RN 229646-14-4 CAPLUS


CN Piperazine, 1-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 229646-15-5 CAPLUS

CN Piperazine, 1-(2-naphthalenylsulfonyl)-4-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 229646-16-6 CAPLUS

CN Piperazine, 1-[(6-chloro-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 229646-17-7 CAPLUS

CN Piperazine, 1-[(6-bromo-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 229646-18-8 CAPLUS

CN Piperazine, 1-(benzo[b]thien-2-ylsulfonyl)-4-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 229646-19-9 CAPLUS

CN Piperazine, 1-[(5-fluorobenzo[b]thien-2-yl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 229646-20-2 CAPLUS


CN Piperazine, 1-[(6-chlorobenzo[b]thien-2-yl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 229646-21-3 CAPLUS

CN Piperazine,


1-[(4-methoxybenzo[b]thien-2-yl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 229646-22-4 CAPLUS


CN Piperazine,

1-[(6-methoxybenzo[b]thien-2-yl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 229646-23-5 CAPLUS

CN Benzo[b]thiophene-3-carboxylic acid, 2-[[4-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-1-piperazinyl]sulfonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 229646-24-6 CAPLUS

CN Piperazine, 1-[[1-[[4-(4-pyridinyl)-4-piperidinyl]methyl]-4-[[3-(trifluoromethyl)benzo[b]thien-2-yl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 229646-25-7 CAPLUS

CN Piperazine,
1-[[3-(3-nitrobenzo[b]thien-2-yl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)


RN 229646-26-8 CAPLUS

CN Piperazine, 1-(2-benzofuranylsulfonyl)-4-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 229646-27-9 CAPLUS

CN Piperazine, 1-[(5-chloro-2-benzofuranyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 229646-28-0 CAPLUS

CN Piperazine, 1-[(2-bromo-6-benzothiazolyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 229646-29-1 CAPLUS

CN Piperazine, 1-([1,1'-biphenyl]-4-ylsulfonyl)-4-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 229646-30-4 CAPLUS

CN Benzoic acid, 4-chloro-3-[[4-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-1-piperazinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 229646-32-6 CAPLUS

CN Benzeneacetic acid,
4-chloro-3-[[4-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-
1-piperazinyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 229646-33-7 CAPLUS

CN Acetamide, N-[6-[[4-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-1-piperazinyl]sulfonyl]-1-naphthalenyl]- (9CI) (CA INDEX NAME)



RN 229646-34-8 CAPLUS


CN Piperazine, 1-[(5-amino-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 229646-35-9 CAPLUS


CN Piperazinone, 4-[[1-[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 229646-36-0 CAPLUS

CN Piperazinone, 4-[(6-bromo-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 229646-37-1 CAPLUS

CN Piperazinone,
4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-
piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 229646-38-2 CAPLUS

CN Piperazinone, 4-(2-naphthalenylsulfonyl)-1-[[1-(4-pyridinyl)-4-
piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 229646-39-3 CAPLUS

CN Piperazinone,
4-[(6-methyl-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-
piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 229646-40-6 CAPLUS

CN Piperazinone, 4-[(6-cyano-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 229646-41-7 CAPLUS

CN Piperazinone,
4-[(6-hydroxy-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 229646-42-8 CAPLUS

CN Piperazinone,
4-[(1-fluoro-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 229646-43-9 CAPLUS

CN 2-Piperazinecarboxylic acid, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 229646-44-0 CAPLUS

CN 2-Piperazinemethanol, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 229646-45-1 CAPLUS


CN 2-Piperazinecarboxylic acid, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 229646-46-2 CAPLUS
 CN 2-Piperazinepropanoic acid, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-.beta.-oxo-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 229646-47-3 CAPLUS
 CN 2-Piperazinecarboxamide, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 229646-48-4 CAPLUS
 CN 2-Piperazinecarboxamide, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-N-[2-(ethylthio)ethyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 229646-49-5 CAPLUS

CN Piperazine, 2-acetyl-4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 229646-50-8 CAPLUS

CN 2-Piperazinecarboxamide, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-N,N-dimethyl-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 229646-51-9 CAPLUS

CN 2-Piperazinecarboxylic acid, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 229646-52-0 CAPLUS

CN 2-Piperazinecarboxylic acid,
4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-
[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 229646-53-1 CAPLUS

CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-(hydroxymethyl)-1-
[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 229646-54-2 CAPLUS

CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-(methoxymethyl)-1-
[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 229646-55-3 CAPLUS

CN Piperazinone,

6-[(acetyloxy)methyl]-4-[(6-chloro-2-naphthalenyl)sulfonyl]-

1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 229646-56-4 CAPLUS

CN 2-Piperazinecarboxylic acid,

4-[[1-[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]-


6-oxo-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, ethyl ester (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 229646-57-5 CAPLUS
 CN 2-Piperazinecarboxylic acid,
 4-[[1-(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]-
 6-oxo-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 229646-58-6 CAPLUS
 CN 2-Piperazinecarboxamide,
 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 229646-59-7 CAPLUS

CN 2-Piperazinecarboxaldehyde,

4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-

[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, 2-oxime (9CI) (CA INDEX NAME)




RN 229646-60-0 CAPLUS

CN Morpholine, 4-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-2-piperazinyl]carbonyl]- (9CI) (CA

INDEX

NAME)




RN 229646-61-1 CAPLUS

CN 2-Piperazinecarboxamide, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-N,N-

dimethyl-6-oxo-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA

INDEX


NAME)



RN 229646-62-2 CAPLUS

CN 2-Piperazinecarboxamide,


4-[(6-chloro-2-naphthalenyl)sulfonyl]-N-methoxy-6-oxo-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 229646-63-3 CAPLUS

CN 4-Piperidinol, 1-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-2-piperazinyl]carbonyl]- (9CI) (CA

INDEX NAME)




RN 229646-64-4 CAPLUS

CN Piperazinone,


6-(aminomethyl)-4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[[1-

(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 229646-65-5 CAPLUS

CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-(4-morpholinylmethyl)-1-[[1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 229646-66-6 CAPLUS

CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-[(dimethylamino)methyl]-1-[[1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)




RN 229646-67-7 CAPLUS


CN Acetamide, N-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-[[1-(4-pyridinyl)-4-piperidinyl)methyl]-2-piperazinyl)methyl]- (9CI) (CA INDEX NAME)



RN 229646-68-8 CAPLUS
 CN Methanesulfonamide,
 N-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-2-piperazinyl]methyl]- (9CI) (CA INDEX NAME)




RN 229646-69-9 CAPLUS
 CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-[(4-hydroxy-1-piperidinyl)methyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 229646-70-2 CAPLUS

CN Piperazinone, 6-(hydroxymethyl)-4-(2-naphthalenylsulfonyl)-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 229646-71-3 CAPLUS


CN Piperazinone, 6-[(acetyloxy)methyl]-4-(2-naphthalenylsulfonyl)-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 229646-72-4 CAPLUS


CN 2-Piperazinecarboxylic acid,
4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-
[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, ethyl ester, (2R)- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.




RN 229646-73-5 CAPLUS
 CN 2-Piperazinecarboxylic acid,
 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-
 [[1-(4-pyridinyl)-4-piperidinyl]methyl]-, ethyl ester, (2S)- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.



RN 229646-74-6 CAPLUS
 CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-(methoxymethyl)-1-
 [[1-(4-pyridinyl)-4-piperidinyl]methyl]-, (6R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 229646-75-7 CAPLUS

CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-(methoxymethyl)-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, (6S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 229646-76-8 CAPLUS

CN 2-Piperazinecarboxylic acid, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 229646-77-9 CAPLUS
 CN 2-Piperazinecarboxylic acid,
 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-
 [[1-(4-pyridinyl)-4-piperidyl]methyl]-, propyl ester (9CI) (CA INDEX
 NAME)




RN 229646-78-0 CAPLUS
 CN 2-Piperazinecarboxylic acid,
 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-
 [[1-(4-pyridinyl)-4-piperidyl]methyl]-, propyl ester, (2R)- (9CI) (CA
 INDEX NAME)

Absolute stereochemistry.




RN 229646-79-1 CAPLUS
 CN 2-Piperazinecarboxylic acid,
 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-
 [[1-(4-pyridinyl)-4-piperidiny]methyl]-, 1-methylethyl ester (9CI) (CA
 INDEX NAME)




RN 229646-80-4 CAPLUS
 CN 2-Piperazinecarboxylic acid,
 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-
 [[1-(4-pyridinyl)-4-piperidiny]methyl]-, 1-methylethyl ester, (2R)-
 (9CI)
 (CA INDEX NAME)


Absolute stereochemistry.



RN 229646-81-5 CAPLUS
 CN 2-Piperazinecarboxylic acid,
 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-
 [[1-(4-pyridinyl)-4-piperidiny]methyl]-, 1,1-dimethylethyl ester (9CI)
 (CA INDEX NAME)



RN 229646-82-6 CAPLUS
 CN Piperazinone,
 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6,6-dimethyl-1-[[1-(4-
 pyridinyl)-4-piperidiny]methyl]- (9CI) (CA INDEX NAME)




RN 229646-83-7 CAPLUS
 CN Piperazine, 1-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 229646-14-4
 CMF C23 H29 Cl N4 O2 S

Double bond geometry as shown.



CM 2

CRN 75-75-2
 CMF C H4 O3 S




RN 229646-84-8 CAPLUS
 CN Piperazinone, 4-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 229646-35-9
 CMF C23 H27 Cl N4 O3 S

Double bond geometry as shown.


09/ 582,442



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 229646-85-9 CAPLUS


CN Piperazinone,

4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 229646-37-1


CMF C25 H27 Cl N4 O3 S



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 229646-86-0 CAPLUS
 CN 2-Piperazinecarboxylic acid,
 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-
 [[1-(4-pyridinyl)-4-piperidinyl)methyl]-, ethyl ester,
 monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 229646-51-9
 CMF C28 H31 Cl N4 O5 S



CM 2

CRN 75-75-2
 CMF C H4 O3 S




RN 229646-87-1 CAPLUS
 CN 2-Piperazinecarboxylic acid,
 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-
 [[1-(4-pyridinyl)-4-piperidinyl)methyl]-, monomethanesulfonate (9CI) (CA
 INDEX NAME)

CM 1

CRN 229646-52-0
 CMF C26 H27 Cl N4 O5 S


09/ 582,442



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 229646-88-2 CAPLUS

CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-(hydroxymethyl)-1-
[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monomethanesulfonate (salt)
(9CI) (CA INDEX NAME)

CM 1

CRN 229646-53-1


CMF C26 H29 Cl N4 O4 S



CM 2

CRN 75-75-2


CMF C H4 O3 S



RN 229646-89-3 CAPLUS
 CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-(methoxymethyl)-1-
 [[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monomethanesulfonate (9CI) (CA
 INDEX NAME)


CM 1

CRN 229646-54-2
 CMF C27 H31 Cl N4 O4 S



CM 2

CRN 75-75-2
 CMF C H4 O3 S




RN 229646-90-6 CAPLUS
 CN Piperazinone,
 6-[(acetyloxy)methyl]-4-[(6-chloro-2-naphthalenyl)sulfonyl]-
 1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monomethanesulfonate (9CI)
 (CA INDEX NAME)

CM 1

CRN 229646-55-3
 CMF C28 H31 Cl N4 O5 S


09/ 582,442



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 229646-91-7 CAPLUS

CN 2-Piperazinecarboxylic acid,

4-[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]-


6-oxo-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, ethyl ester,
monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 229646-56-4

CMF C26 H31 Cl N4 O5 S


Double bond geometry as shown.



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 229646-92-8 CAPLUS

CN 2-Piperazinecarboxylic acid,

4-[[[(1E)-2-(4-chlorophenyl)ethenyl]sulfonyl]-

6-oxo-1-[[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monomethanesulfonate


(9CI) (CA INDEX NAME)

CM 1

CRN 229646-57-5

CMF C24 H27 Cl N4 O5 S


Double bond geometry as shown.



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 229646-93-9 CAPLUS


CN Morpholine, 4-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-2-piperazinyl]carbonyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 229646-60-0

CMF C30 H34 Cl N5 O5 S


09/ 582,442



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 229646-94-0 CAPLUS


CN Piperazinone,

6-(aminomethyl)-4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 229646-64-4

CMF C26 H30 Cl N5 O3 S



CM 2


CRN 75-75-2
CMF C H4 O3 S



RN 229646-95-1 CAPLUS
CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-(4-morpholinylmethyl)-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 229646-65-5
CMF C30 H36 Cl N5 O4 S



CM 2

CRN 75-75-2
CMF C H4 O3 S




RN 229646-96-2 CAPLUS
CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-[(dimethylamino)methyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

09/ 582,442

CM 1

CRN 229646-66-6


CMF C28 H34 Cl N5 O3 S



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 229646-97-3 CAPLUS

CN Acetamide, N-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-2-piperazinyl]methyl]-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 229646-67-7


CMF C28 H32 Cl N5 O4 S



CM 2

09/ 582,442


CRN 75-75-2
CMF C H4 O3 S



RN 229646-98-4 CAPLUS
CN Methanesulfonamide,
N-[[4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-2-piperazinyl]methyl]-,
monomethanesulfonate (9CI) (CA INDEX NAME)


CM 1

CRN 229646-68-8
CMF C27 H32 Cl N5 O5 S2



CM 2

CRN 75-75-2
CMF C H4 O3 S




RN 229646-99-5 CAPLUS
CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-[(4-hydroxy-1-piperidinyl)methyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]-,
monomethanesulfonate (salt) (9CI) (CA INDEX NAME)

CM 1


09/ 582,442

CRN 229646-69-9
CMF C31 H38 Cl N5 O4 S



CM 2

CRN 75-75-2
CMF C H4 O3 S




RN 229647-00-1 CAPLUS
CN 2-Piperazinecarboxylic acid,
4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-
[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, ethyl ester, (2R)-,
monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 229646-72-4
CMF C28 H31 Cl N4 O5 S


Absolute stereochemistry.



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 229647-01-2 CAPLUS

CN 2-Piperazinecarboxylic acid,

4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-


[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, ethyl ester, (2S)-,
monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 229646-73-5

CMF C28 H31 Cl N4 O5 S


Absolute stereochemistry.



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 229647-02-3 CAPLUS


CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-(methoxymethyl)-1-
 [[1-(4-pyridinyl)-4-piperidinyl]methyl]-, (6R)-, monomethanesulfonate
 (9CI) (CA INDEX NAME)

CM 1

CRN 229646-74-6

CMF C27 H31 Cl N4 O4 S


Absolute stereochemistry.



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 229647-03-4 CAPLUS


CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-(methoxymethyl)-1-
[[1-(4-pyridinyl)-4-piperidinyl]methyl]-, (6S)-, monomethanesulfonate
(9CI) (CA INDEX NAME)

CM 1

CRN 229646-75-7

CMF C27 H31 Cl N4 O4 S


Absolute stereochemistry.



CM 2

CRN 75-75-2

CMF C H4 O3 S




RN 229647-04-5 CAPLUS
 CN 2-Piperazinecarboxylic acid,
 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-
 [[1-(4-pyridinyl)-4-piperidinyl]methyl]-, (2R)-, monomethanesulfonate
 (9CI) (CA INDEX NAME)

CM 1


CRN 229646-76-8
 CMF C26 H27 Cl N4 O5 S

Absolute stereochemistry.



CM 2

CRN 75-75-2
 CMF C H4 O3 S




RN 229647-05-6 CAPLUS
 CN 2-Piperazinecarboxylic acid,
 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-
 [[1-(4-pyridinyl)-4-piperidinyl)methyl]-, propyl ester, (2R)-,
 monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1


CRN 229646-78-0
 CMF C29 H33 Cl N4 O5 S

Absolute stereochemistry.




CM 2

CRN 75-75-2
 CMF C H4 O3 S



RN 229955-03-7 CAPLUS
 CN Piperazinone, 4-[[[(1E)-2-(4-chlorophenyl)ethenyl)sulfonyl]-6-(methoxymethyl)-1-[[1-(4-pyridinyl)-4-piperidinyl)methyl]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 229647-18-1P 229955-04-8P 229955-05-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of arom. compds. having cyclic amino or salts thereof as FXa inhibitors)

RN 229647-18-1 CAPLUS

CN 2-Piperazinecarboxaldehyde,

4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-oxo-1-


[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 229955-04-8 CAPLUS

CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-[(2,5-dioxo-1-pyrrolidinyl)methyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI)


(CA INDEX NAME)



RN 229955-05-9 CAPLUS

CN Piperazinone, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-6-[[[4-

methylphenyl)sulfonyl]oxy)methyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

15

REFERENCE(S):

- (1) Adir Et Co; FR 2601364 A CAPLUS
 - (2) Adir Et Co; EP 262993 A CAPLUS
 - (3) Adir Et Co; US 4820707 A CAPLUS
 - (6) Glaxo Group Ltd; EP 542363 A CAPLUS
 - (7) Glaxo Group Ltd; EP 612313 A CAPLUS
- ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1999:113671 CAPLUS

DOCUMENT NUMBER: 130:168388

TITLE: Pyridyl- and pyrimidyl-heterocyclic compounds inhibiting oxidosqualene cyclase

INVENTOR(S): Newcombe, Nicholas John; Johnson, Michael Clyde

PATENT ASSIGNEE(S): Zeneca Limited, UK

SOURCE: PCT Int. Appl., 43 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent


LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9906395	A1	19990211	WO 1998-GB2196	19980723
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,				

CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 AU 9885471 A1 19990222 AU 1998-85471 19980723
 EP 1000057 A1 20000517 EP 1998-936494 19980723
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI
 PRIORITY APPLN. INFO.: GB 1997-15892 19970729
 WO 1998-GB2196 19980723
 OTHER SOURCE(S): MARPAT 130:168388
 GI




AB The title compds. I [G = CH, N; R1 = H, halo, (1-6C)alkyl, halo(1-6C)alkyl, cyano, nitro, (1-6C)alkoxycarbonyl, NR3R4 (R3, R4 = H, (1-6C)alkyl), up to 3 R1 groups may be present; T1 = CH, N; T2, T3 = N, CR
 (R = H, hydroxyl, (1-4)alkyl); either ring contg. T2 or T3 is optionally substituted with an oxo group; R2 = H, (1-4C)alkyl; Q = SO2, CO, CH2; Ar = five or six-membered heterocycle contg. up to 3 heteroatoms selected from nitrogen, oxygen and sulfur, Ph, phenyl(2-6C)alkenyl, naphthyl in which any Ar group is optionally substituted by one or more substituents selected from (1-6C)alkyl, halo, halo(1-6C)alkyl, (1-6C)alkoxy, (1-6C)alkoxycarbonyl, cyano, (1-6C)alkylamido, nitro, NR3R4 (R3, R4 = H, (1-4C)alkyl) both T2 and T3 are not N and when T2 is CR then T1 is not CH], useful in inhibiting oxidosqualene cyclase (no data), were prepd. E.g.,
 1-(4-chlorophenylsulfonyl)-4-[1-(2-methylpyrimidin-4-yl)piperazin-4-ylmethyl]piperidine was prepd.
 IT 220358-83-8P 220358-84-9P 220358-85-0P
 220358-86-1P 220358-88-3P 220358-89-4P
 220358-90-7P 220358-91-8P 220358-92-9P
 220358-93-0P 220358-94-1P 220358-95-2P
 220358-96-3P 220359-01-3P 220359-03-5P
 220359-04-6P 220359-05-7P 220359-06-8P
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of pyridyl- and pyrimidyl-heterocyclic compds. as inhibitors of oxidosqualene cyclase)
 RN 220358-83-8 CAPLUS
 CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[[1-(2-methyl-4-pyrimidinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 220358-84-9 CAPLUS

CN Piperazine, 1-[[1-(2-methyl-4-pyrimidinyl)-4-piperidinyl]methyl]-4-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 220358-85-0 CAPLUS

CN Piperazine,
1-[(4-fluorophenyl)sulfonyl]-4-[[1-(2-methyl-4-pyrimidinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 220358-86-1 CAPLUS

CN Piperazine,
1-[(4-methoxyphenyl)sulfonyl]-4-[[1-(2-methyl-4-pyrimidinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 220358-88-3 CAPLUS

CN Piperazine,
1-[[4-hydroxy-1-(2-methyl-4-pyrimidinyl)-4-piperidinyl]methyl]-4-[[4-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 220358-89-4 CAPLUS


CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[[4-hydroxy-1-(2-methyl-4-pyrimidinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 220358-90-7 CAPLUS


CN Piperazine,
1-[[4-hydroxy-1-(2-methyl-4-pyrimidinyl)-4-piperidinyl]methyl]-
4-(phenylsulfonyl)- (9CI) (CA INDEX NAME)

RN 220358-91-8 CAPLUS

CN Piperazine,
1-[[4-hydroxy-1-(2-methyl-4-pyrimidinyl)-4-piperidinyl]methyl]-
4-[(4-methoxyphenyl)sulfonyl]- (9CI) (CA INDEX NAME)


RN 220358-92-9 CAPLUS

CN Piperazine,
1-[[4-hydroxy-1-(2-methyl-4-pyrimidinyl)-4-piperidinyl]methyl]-
4-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 220358-93-0 CAPLUS

CN Piperazine, 1-[(4-chlorophenyl)sulfonyl]-4-[[4-hydroxy-1-(2-methyl-4-pyrimidinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 220358-94-1 CAPLUS

CN Piperazine, 1-[(4-chlorophenyl)sulfonyl]-4-[[1-(2,6-dimethyl-4-pyrimidinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 220358-95-2 CAPLUS


CN Piperazinone, 4-[(4-bromophenyl)sulfonyl]-1-[[1-(2-methyl-4-pyrimidinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 220358-96-3 CAPLUS


CN Piperazinone, 4-[[1-(2-methyl-4-pyrimidinyl)-4-piperidinyl]methyl]-1-[[4-

(trifluoromethyl)phenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 220359-01-3 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[[1-(6-methyl-4-pyrimidinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 220359-03-5 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[[1-(2-fluoro-4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 220359-04-6 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[[1-(2,6-dimethyl-4-pyrimidinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




RN 220359-05-7 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)



RN 220359-06-8 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[[1-(2-chloro-4-pyridinyl)-4-piperidinyl]methyl]- (9CI) (CA INDEX NAME)




IT 203522-53-6 220359-08-0

RL: RCT (Reactant)

(prepn. of pyridyl- and pyrimidyl-heterocyclic compds. as inhibitors of oxidosqualene cyclase)


RN 203522-53-6 CAPLUS

CN Piperazine, 1-[(4-chlorophenyl)sulfonyl]-4-[[1-(2,6-dimethyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 220359-08-0 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[[1-(6-methyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



IT 220359-13-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of pyridyl- and pyrimidyl-heterocyclic compds. as inhibitors

of

oxidosqualene cyclase)

RN 220359-13-7 CAPLUS

CN Piperazine, 1-[[1-(2-methyl-4-pyrimidinyl)-4-piperidinyl]methyl]-4-[[4-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT:

6

REFERENCE (S):

- (1) Brown, G; WO 9706802 A 1997 CAPLUS
 - (2) Brown, G; WO 9728128 A 1997 CAPLUS
 - (3) Brown, G; WO 9806705 A 1998 CAPLUS
 - (4) Brown, G; WO 9835956 A 1998 CAPLUS
 - (5) Brown, G; WO 9835959 A 1998 CAPLUS
- ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1998:568819 CAPLUS

DOCUMENT NUMBER: 129:189344

TITLE: 1-(Arylsulfonyl)-4-[[1-(4-pyridyl)piperazin-4-yl]carbonyl]piperazines and analogs useful as oxido-squalene cyclase inhibitors

INVENTOR(S): Brown, George Robert

PATENT ASSIGNEE(S): Zeneca Limited, UK

SOURCE: PCT Int. Appl., 45 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent



LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9835956	A1	19980820	WO 1998-GB405	19980209
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,				

NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
 UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI,
 FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM,
 GA, GN, ML, MR, NE, SN, TD, TG
 AU 9859996 A1 19980908 AU 1998-59996 19980209
 EP 966460 A1 19991229 EP 1998-903174 19980209
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, FI
 ZA 9801177 A 19980813 ZA 1998-1177 19980212
 PRIORITY APPLN. INFO.: GB 1997-2946 19970213
 GB 1997-15734 19970726
 GB 1997-19237 19970911
 WO 1998-GB405 19980209
 OTHER SOURCE(S): MARPAT 129:189344
 GI



AB This invention concerns heterocyclic compds. I [R = halo, cyano, NO₂, CO₂H, alkyl, alkoxy, alkanoyl, alkoxycarbonyl, haloalkyl; R₁ = H, (di)(alkyl)amino, halo, cyano, NO₂, CO₂H, alkyl, alkoxy, alkanoyl, alkylthio, etc.; m = 1 or 2; A = bond or C1-4 alkylene; X, Y = N, CR₂; R₂ = H, alk(en/yn)yl; Z = N, CH; Q = (un)substituted heteroaryl, Ph, naphthyl, etc.; rings contg. X, Y, and Z may be substituted; with several provisos], which are useful for inhibiting oxido-squalene cyclase, processes for their prepn., and pharmaceutical compns. contg. them. The invention is also concerned with such heterocyclic compds. capable of inhibiting cholesterol biosynthesis, and hence lowering cholesterol levels in blood plasma. The invention also relates to methods of using such compds. in diseases and medical conditions such as hypercholesterolemia and atherosclerosis. For instance, chlorination of 1-[(4-bromophenyl)sulfonyl]-4-[[1-(4-pyridyl)piperidin-4-yl]carbonyl]piperazine with N-chlorosuccinimide in MeCN gave title compd. II. The latter gave about 79% inhibition of rat microsomal oxido-squalene cyclase in vitro at 0.01 .mu.M, and likewise gave about 79% inhibition of rat cholesterol biosynthesis in vivo at 2 mg/kg orally. The compds. showed no overt toxicity at several multiples of the min. ID. Several std. pharmaceutical


formulations are described.

IT 211819-82-8P 211819-83-9P 211819-84-0P
211819-86-2P 211819-87-3P 211819-88-4P
211819-89-5P 211819-90-8P 211819-95-3P
211819-96-4P

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of (arylsulfonyl)[(pyridylpiperazinyl)carbonyl]piperazines and analogs as oxido-squalene cyclase inhibitors)


RN 211819-82-8 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[[1-(3-chloro-4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 211819-83-9 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[[1-(3-bromo-4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 211819-84-0 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[[1-(5-chloro-2-methyl-4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 211819-86-2 CAPLUS

CN Piperazine,
1-[[1-(5-bromo-2-methyl-4-pyridinyl)-4-piperidinyl]carbonyl]-4-
[(4-bromophenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 211819-87-3 CAPLUS

CN Piperazine, 1-[[1-(3-chloro-4-pyridinyl)-4-piperidinyl]carbonyl]-4-[(3-fluorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 211819-88-4 CAPLUS

CN Piperazine, 1-[[1-(3-chloro-4-pyridinyl)-4-piperidinyl]carbonyl]-4-[(4-fluorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 211819-89-5 CAPLUS

CN Piperazine, 1-[[1-(3-chloro-4-pyridinyl)-4-piperidinyl]carbonyl]-4-[(4-methoxyphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 211819-90-8 CAPLUS

CN Piperazine, 1-[[1-(3-chloro-4-pyridinyl)-4-piperidinyl]carbonyl]-4-[(4-methylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 211819-95-3 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[[1-(3-fluoro-4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 211819-96-4 CAPLUS

CN Piperazine, 1-[[1-(3-fluoro-4-pyridinyl)-4-piperidinyl]carbonyl]-4-[[4-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




IT 179050-10-3

RL: RCT (Reactant)

(starting material; prepn. of
(arylsulfonyl)[(pyridylpiperazinyl)carbon
yl]piperazines and analogs as oxido-squalene cyclase inhibitors)

RN 179050-10-3 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1998:126242 CAPLUS

DOCUMENT NUMBER: 128:192661

OTHER SOURCE(S) : MARPAT 128:192661
GI

AB Title compds. [I; T1, T3 = N, CR; R = H, alkyl, alkenyl, alkynyl; R1 = H, amino, halo, cyano, alkyl, alkylamino, dialkylamino, alkoxy; m = 1, 2; T2 = CH, N; Q = (substituted) Ph, naphthyl, phenylalkenyl, heteroaryl; Q1 = (CH2)a; Q2 = (CH2)b; Q3 = (CH2)c; Q4 = (CH2)d; X = O, CO, S, SO, SO2,

CH2; a, b = 2, 3; c, d = 1, 2], were prepd. as antihypercholesteremics. Thus, 4-[1-(4-pyrimidinyl)piperazin-4-ylcarbonyl]piperidine in CH2Cl2 was treated with a mixt. of 4-chlorophenylsulfonyl chloride and Et3N in CH2Cl2

under ice cooling followed by stirring for 18 h at room temp. to give 26% 1-(4-chlorophenylsulfonyl)-4-[1-(4-pyrimidinyl)piperazin-4-ylcarbonyl]piperidine. The latter at 5 mg/kg orally in rats gave 72% inhibition of cholesterol biosynthesis.

IT 179050-27-2P 179050-28-3P 179050-48-7P
 179050-49-8P 188526-43-4P 188526-44-5P
 188526-45-6P 188526-46-7P 188526-47-8P
 188526-48-9P 188526-49-0P 188526-50-3P
 188526-51-4P 188526-52-5P 188526-53-6P
 188526-54-7P 188526-55-8P 188526-56-9P
 188526-57-0P 188526-58-1P 188526-59-2P
 188526-60-5P 188526-61-6P 188526-62-7P
 188526-63-8P 188526-65-0P 188526-66-1P
 188526-67-2P 188526-68-3P 188526-69-4P
 188526-70-7P 188526-71-8P 188526-76-3P
 188526-77-4P 188526-78-5P 188526-79-6P
 188526-80-9P 188526-81-0P 188526-82-1P
 188526-83-2P 188526-84-3P 188526-85-4P
 188526-86-5P 188526-87-6P 188526-88-7P
 188526-89-8P 188526-93-4P 188526-95-6P
 188526-96-7P 203522-46-7P 203522-48-9P
 203522-51-4P 203522-53-6P 203522-54-7P
 203522-55-8P 203522-78-5P 203522-79-6P
 203522-80-9P 203522-81-0P 203522-83-2P
 203522-85-4P 203522-87-6P 203522-89-8P
 203522-93-4P 203522-96-7P 203522-97-8P
 203522-98-9P 203523-00-6P 203523-02-8P
 203523-05-1P 203523-06-2P 203574-71-4P
 203574-72-5P


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of pyrimidinylpiperidinylcarbonylpiperazines and related compds. as inhibitors of oxidosqualene cyclase)

RN 179050-27-2 CAPLUS

CN Piperazine,

1-[[1-(2-amino-6-methyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]-4-(2-naphthalenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 179050-28-3 CAPLUS

CN Piperazine,

1-[[2-(4-chlorophenyl)ethenyl]sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidiny]carbonyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 179050-48-7 CAPLUS


CN Piperazine,

1-[(6-chloro-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-49-8 CAPLUS

CN Piperazine, 1-[[1-(2-amino-4-pyrimidinyl)-4-piperidiny]carbonyl]-4-[(6-chloro-2-naphthalenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 188526-43-4 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[[1-(2-methyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-44-5 CAPLUS

CN Piperazine, 1-(phenylmethyl)-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-45-6 CAPLUS

CN Piperazine, 1-[(4-cyanophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-46-7 CAPLUS

CN Piperazine, 1-[(2-chloro-4-cyanophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-47-8 CAPLUS

CN Piperazine, 1-[(3,4-dichlorophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-48-9 CAPLUS

CN Piperazine, 1-[(4-methoxyphenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-49-0 CAPLUS

CN Piperazine, 1-[(4-chlorophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-50-3 CAPLUS

CN Piperazine, 1-[(2-cyanophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-51-4 CAPLUS

CN Piperazine, 1-[(2,4-difluorophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-52-5 CAPLUS

CN Piperazine, 1-[(4-butoxyphenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-53-6 CAPLUS

CN Piperazine, 1-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-54-7 CAPLUS

CN Piperazine, 1-[[4-(1-methylethyl)phenyl]sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-55-8 CAPLUS

CN Piperazine, 1-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]-4-(2-thienylsulfonyl)- (9CI) (CA INDEX NAME)




RN 188526-56-9 CAPLUS

CN Piperazine, 1-[(5-chloro-2-thienyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-57-0 CAPLUS

CN Piperazine, 1-[(2,5-dichloro-3-thienyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-58-1 CAPLUS

CN Piperazine, 1-[(5-bromo-2-thienyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-59-2 CAPLUS

CN Piperazine, 1-[(4,5-dibromo-2-thienyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-60-5 CAPLUS

CN Piperazine, 1-[(4,5-dichloro-2-thienyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-61-6 CAPLUS

CN Piperazine, 1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 188526-62-7 CAPLUS


CN Piperazine, 1-[[5-(2-pyridinyl)-2-thienyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-63-8 CAPLUS

CN Piperazine, 1-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 188526-65-0 CAPLUS
 CN Piperazine, 1-[(4-fluoro-3,5-dimethylphenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-66-1 CAPLUS
 CN Piperazine, 1-[(3,6-dibromo-2,5-difluorophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-67-2 CAPLUS

CN Piperazine, 1-[(4-iodophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-68-3 CAPLUS

CN Acetamide, N-[4-[[4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]-1-piperazinyl]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 188526-69-4 CAPLUS

CN Piperazine, 1-(phenylsulfonyl)-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-70-7 CAPLUS

CN Piperazine, 1-[(4-ethylphenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-71-8 CAPLUS

CN Piperazine, 1-[(4-propylphenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-76-3 CAPLUS

CN Piperazine, 1-[(4-methylphenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-77-4 CAPLUS

CN Piperazine, 1-[(2,5-dibromophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-78-5 CAPLUS

CN Piperazine, 1-[[3,5-bis(trifluoromethyl)phenyl]sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-79-6 CAPLUS

CN Piperazine, 1-[(4-nitrophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-80-9 CAPLUS

CN Piperazine, 1-[(4-chloro-3-nitrophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-81-0 CAPLUS

CN Benzoic acid, 2-[[4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]-1-piperazinyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 188526-82-1 CAPLUS

CN Piperazine, 1-[(3,4-dibromophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-83-2 CAPLUS

CN Piperazine, 1-[[[1-(4-pyrimidinyl)-4-piperidiny]carbonyl]-4-[(2,4,5-trichlorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 188526-84-3 CAPLUS

CN Piperazine, 1-[[[1-(4-pyrimidinyl)-4-piperidiny]carbonyl]-4-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 188526-85-4 CAPLUS

CN Piperazine, 1-[(3,5-dichlorophenyl)sulfonyl]-4-[[[1-(4-pyrimidinyl)-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-86-5 CAPLUS

CN Piperazine,
1-[(2-chloro-4-fluorophenyl)sulfonyl]-4-[[[1-(4-pyrimidinyl)-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-87-6 CAPLUS

CN Piperazine, 1-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]-4-[[4-(trifluoromethoxy)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 188526-88-7 CAPLUS

CN Piperazine, 1-[[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-89-8 CAPLUS

CN 2-Piperazinecarboxylic acid, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 188526-93-4 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[[1-(5-chloro-4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-95-6 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-96-7 CAPLUS

CN Piperazine, 1-[(4-fluorophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)




RN 203522-46-7 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[[4-methyl-1-(4-pyrimidinyl)-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)




RN 203522-48-9 CAPLUS

CN Piperazine, 1-[[1-(2,6-dimethyl-4-pyrimidinyl)-4-piperidiny]carbonyl]-4-[(4-fluorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 203522-51-4 CAPLUS

CN Piperazine, 1-[[1-(2,6-dimethyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]-4-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 203522-53-6 CAPLUS

CN Piperazine, 1-[(4-chlorophenyl)sulfonyl]-4-[[1-(2,6-dimethyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 203522-54-7 CAPLUS

CN Piperazine, 1-[[1-(2,6-dimethyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]-4-[[4-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203522-55-8 CAPLUS

CN Piperazine, 1-[[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl]-4-[[1-(2,6-dimethyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 203522-78-5 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[[1-(2-propyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 203522-79-6 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[[1-(2-ethyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 203522-80-9 CAPLUS

CN Piperazine, 1-[(4-chlorophenyl)sulfonyl]-4-[[1-(2-methyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 203522-81-0 CAPLUS


CN Piperazine,
1-[(4-fluorophenyl)sulfonyl]-4-[[1-(2-methyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 203522-83-2 CAPLUS
CN Piperazine, 1-[(3-chloro-4-fluorophenyl)sulfonyl]-4-[[1-(2-methyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 203522-85-4 CAPLUS
CN Piperazine,
1-[(3-fluorophenyl)sulfonyl]-4-[[1-(2-methyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 203522-87-6 CAPLUS
CN Piperazine, 1-[[1-(2-methyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]-4-[[4-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 203522-89-8 CAPLUS
CN Piperazine, 1-[[1-(2-methyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]-4-(2-thienylsulfonyl)- (9CI) (CA INDEX NAME)




RN 203522-93-4 CAPLUS

CN Piperazine, 1-[(5-chloro-2-thienyl)sulfonyl]-4-[[1-(2,6-dimethyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 203522-96-7 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[[1-(2-ethyl-4-pyrimidinyl)-4-methyl-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 203522-97-8 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[[4-ethyl-1-(2-methyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 203522-98-9 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[[1-(2-methyl-4-pyrimidinyl)-4-(2-propenyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 203523-00-6 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[[4-methyl-1-(2-methyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 203523-02-8 CAPLUS

CN Piperazine, 1-[[1-(6-methyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]-4-(phenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 203523-05-1 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[[1-[6-(methylamino)-4-pyrimidinyl]-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 203523-06-2 CAPLUS

CN Piperazine,

1-[[1-[6-(methylamino)-4-pyrimidinyl]-4-piperidinyl]carbonyl]-
4-[[4-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 203574-71-4 CAPLUS

CN Piperazine, 1-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]-4-[[2,2,2-trifluoroethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)

F₃C-CH₂-D₁

RN 203574-72-5 CAPLUS

CN Piperazine, 1-[(2-chlorothieryl)sulfonyl]-4-[[1-(2,6-dimethyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




IT 203520-91-6P 203520-93-8P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of pyrimidinylpiperidinylcarbonylpiperazines and related
comps. as inhibitors of oxidosqualene cyclase)


RN 203520-91-6 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[[1-(6-chloro-4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 203520-93-8 CAPLUS

CN Piperazine, 1-[[1-(6-chloro-4-pyrimidinyl)-4-piperidinyl]carbonyl]-4-[[4-(trifluoromethyl)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1997:542445 CAPLUS

DOCUMENT NUMBER: 127:234328


TITLE: Preparation of pyridylpiperidinylcarbonylpiperazines
and related compounds as
antithrombotics/anticoagulant

INVENTOR(S): s.
Faull, Alan Wellington

PATENT ASSIGNEE(S): Zeneca Ltd., UK; Faull, Alan Wellington
 SOURCE: PCT Int. Appl., 46 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9729104	A1	19970814	WO 1997-GB270	19970131
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9715534	A1	19970828	AU 1997-15534	19970131
EP 880516	A1	19981202	EP 1997-901728	19970131
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2000504682	T2	20000418	JP 1997-528261	19970131
US 6022869	A	20000208	US 1998-117673	19980804
PRIORITY APPLN. INFO.:			GB 1996-2294	19960205
			WO 1997-GB270	19970131

OTHER SOURCE(S): MARPAT 127:234328
 GI




AB Title compds. [I; T1, G1, G2 = CH, N; R1 = halo, CF3, OCF3, cyano, amino, OH, NO2, alkyl, alkoxy; L1 = (substituted) alkylene, 1,2-cycloalkylene, alkylencarbonyl; R2, R3 = H, alkyl; R2R3 = (substituted) alkylene, methylenecarbonyl; R4 = CONR7(CH2)nSOPR8, CONH(CH2)qNR9R10, AY1; R7 = H; R8 = alkyl, Ph, phenylalkyl; R7R8 = alkylene; R9, R10 = H, alkyl, Ph, alkylphenyl, SOPR8, heteroaryl, COR11; R11 = H, alkyl, Ph, alkylphenyl; R14-R16 = H, alkyl; A = alkylene; Y1 = SOPR8, NHSO2R8, pyrrolidin-1-yl, piperidino, morpholino, piperazin-1-yl, etc.; m, p = 0-2; q = 2-4; X1 = O, S, SO, SO2, CO, CO2, CONR14, CR15R16; Q = (substituted) Ph, naphthyl, phenylalkyl, heterocyclyl], were prepd. Thus, 4-(6-bromonaphth-2-ylsulfonyl)-2-carboxy-1-[1-(4-pyridyl)piperidin-4-ylcarbonyl]piperazine (prepn. given) in DMF was treated with N-3-dimethylaminopropyl-N-ethylcarbodiimide, 1-hydroxybenzotriazole, and 2-(ethylthio)amine in DMF to give 44% 4-(6-bromonaphth-2-ylsulfonyl)-2-[N-2-(ethylthioethyl)carbamoyl]-1-[1-(4-pyridyl)piperidin-4-ylcarbonyl]piperazine. The latter inhibited Factor Xa with IC50 = 0.004


.mu.M.
 IT 195153-83-4P 195153-84-5P 195153-85-6P
 195153-86-7P 195153-87-8P
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (prepn. of pyridylpiperidinylcarbonylpiperazines and related compds.
 as antithrombotics/anticoagulants)
 RN 195153-83-4 CAPLUS
 CN 2-Piperazinecarboxamide, 4-[(6-bromo-2-naphthalenyl)sulfonyl]-N-[2-(ethylthio)ethyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 195153-84-5 CAPLUS
 CN Thiomorpholine, 4-[[4-[(6-bromo-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-2-piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 195153-85-6 CAPLUS
 CN Thiomorpholine, 4-[[4-[(6-bromo-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-2-piperazinyl]carbonyl]-, 1,1-dioxide (9CI) (CA INDEX NAME)




RN 195153-86-7 CAPLUS

CN 2-Piperazinecarboxamide, 4-[(6-bromo-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-N-(tetrahydro-1,1-dioxido-3-thienyl)- (9CI) (CA INDEX NAME)



RN 195153-87-8 CAPLUS

CN 2-Piperazinecarboxamide, 4-[(6-bromo-2-naphthalenyl)sulfonyl]-N-[2-(dimethylamino)ethyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



IT 179050-61-4P 179050-62-5P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of pyridylpiperidinylcarbonylpiperazines and related compds.


as

antithrombotics/anticoagulants)

RN 179050-61-4 CAPLUS

CN 2-Piperazinecarboxylic acid,


4-[(6-bromo-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 179050-62-5 CAPLUS

CN 2-Piperazinecarboxylic acid,

4-[(6-bromo-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



L4 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2001 ACS



ACCESSION NUMBER: 1997:259776 CAPLUS

DOCUMENT NUMBER: 126:238391

TITLE: Preparation of (di)azinylcarbonyl(di)azines as

INVENTOR(S): oxidosqualene cyclase inhibitors
 Brown, George Robert; Stokes, Elaine Sophie
 Elisabeth;
 PATENT ASSIGNEE(S): Waterson, David; Wood, Robin
 Zeneca Limited, UK; Brown, George Robert; Stokes,
 Elaine Sophie Elisabeth; Waterson, David; Wood, Robin
 SOURCE: PCT Int. Appl., 88 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9706802	A1	19970227	WO 1996-GB1985	19960814
W: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, US, UZ, VN, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA CA 2226735 AA 19970227 CA 1996-2226735 19960814 AU 9667485 A1 19970312 AU 1996-67485 19960814 EP 844877 A1 19980603 EP 1996-927782 19960814 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI CN 1193276 A 19980916 CN 1996-196278 19960814 JP 11511161 T2 19990928 JP 1996-509050 19960814 US 6090813 A 20000718 US 1998-11718 19980213 PRIORITY APPLN. INFO.: GB 1995-16709 19950815 WO 1996-GB1985 19960814 OTHER SOURCE(S): MARPAT 126:238391 GI				



AB Title compds. [I; A = bond or alkylene; G, T1-T3 = CH or N (T2 .noteq. T3 = CH); Q = cycloalkyl, heterocyclyl, phenyl(alkyl), etc.; R1 = H, halo, NH2, cyano, alkyl, alkoxy; X = O, SOO-2, CO, CONH, etc.; G1, G2 = 1 or 2 CH2; G3, G4 = 0 or 1 CH2; m = 1 or 2] were prepd. Thus, 1-(4-pyridyl)piperidine-4-carbonyl chloride (prepn. given) was amidated by 3-methyl-1-(2-naphthylsulfonyl)piperazine to give title compd. II. Data for biol. activity of 1 prepd. I were given.


IT 179049-56-0P 179049-81-1P 179049-82-2P
 179049-93-5P 179049-94-6P 179049-95-7P
 179049-96-8P 179049-98-0P 179049-99-1P
 179050-00-1P 179050-03-4P 179050-05-6P
 179050-06-7P 179050-07-8P 179050-09-0P
 179050-10-3P 179050-11-4P 179050-12-5P
 179050-23-8P 179050-27-2P 179050-28-3P
 179050-30-7P 179050-31-8P 179050-34-1P
 179050-40-9P 179050-42-1P 179050-46-5P
 179050-48-7P 179050-49-8P 188526-29-6P
 188526-30-9P 188526-31-0P 188526-32-1P
 188526-33-2P 188526-34-3P 188526-35-4P
 188526-36-5P 188526-38-7P 188526-41-2P
 188526-42-3P 188526-43-4P 188526-44-5P
 188526-45-6P 188526-46-7P 188526-47-8P
 188526-48-9P 188526-49-0P 188526-50-3P
 188526-51-4P 188526-52-5P 188526-53-6P
 188526-54-7P 188526-55-8P 188526-56-9P
 188526-57-0P 188526-58-1P 188526-59-2P
 188526-60-5P 188526-61-6P 188526-62-7P
 188526-63-8P 188526-64-9P 188526-65-0P
 188526-66-1P 188526-67-2P 188526-68-3P
 188526-69-4P 188526-70-7P 188526-71-8P
 188526-72-9P 188526-73-0P 188526-74-1P
 188526-75-2P 188526-76-3P 188526-77-4P
 188526-78-5P 188526-79-6P 188526-80-9P
 188526-81-0P 188526-82-1P 188526-83-2P
 188526-84-3P 188526-85-4P 188526-86-5P
 188526-87-6P 188526-88-7P 188526-89-8P
 188526-93-4P 188526-95-6P 188526-96-7P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of (di)azinyldicarbonyl(di)azines as oxidosqualene cyclase inhibitors)


RN 179049-56-0 CAPLUS

CN Piperazine, 1-(2-naphthalenylsulfonyl)-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179049-81-1 CAPLUS

CN Piperazine, 1-[(8-chloro-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 179049-82-2 CAPLUS


CN 2-Piperazinecarboxylic acid, 1-(2-naphthalenylsulfonyl)-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 179049-93-5 CAPLUS


CN Piperazine, 1-[[2-(4-methylphenyl)ethenyl]sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 179049-94-6 CAPLUS
 CN Piperazine,
 1-[[2-(2-methylphenyl)ethenyl]sulfonyl]-4-[[1-(4-pyridinyl)-4-
 piperidiny]carbonyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 179049-95-7 CAPLUS
 CN Piperazine,
 1-[[2-(4-fluorophenyl)ethenyl]sulfonyl]-4-[[1-(4-pyridinyl)-4-
 piperidiny]carbonyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 179049-96-8 CAPLUS
 CN Piperazine,
 1-[[2-(2-chlorophenyl)ethenyl]sulfonyl]-4-[[1-(4-pyridinyl)-4-
 piperidiny]carbonyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 179049-98-0 CAPLUS

CN Piperazine, 1-[[2-(3,4-dichlorophenyl)ethenyl]sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 179049-99-1 CAPLUS

CN Piperazine, 1-[[2-(4-bromophenyl)ethenyl]sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 179050-00-1 CAPLUS


CN Piperazine, 1-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-4-[[2-(4-(trifluoromethyl)phenyl)ethenyl]sulfonyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 179050-03-4 CAPLUS

CN Piperazine, 1-[(7-ethoxy-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-05-6 CAPLUS

CN Piperazine, 1-[(6-chloro-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-06-7 CAPLUS

CN Piperazine, 1-[(6-bromo-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-07-8 CAPLUS

CN Piperazine, 1-[(6-methoxy-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-09-0 CAPLUS

CN Piperazine, 1-[(6-fluoro-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-10-3 CAPLUS


CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-11-4 CAPLUS
 CN Piperazine, 1-([1,1'-biphenyl]-4-ylsulfonyl)-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-12-5 CAPLUS
 CN Piperazine, 1-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 179050-23-8 CAPLUS
 CN Piperazine, 2-methyl-4-(2-naphthalenylsulfonyl)-1-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 179050-27-2 CAPLUS
 CN Piperazine,
 1-[[1-(2-amino-6-methyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]-
 4-(2-naphthalenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 179050-28-3 CAPLUS

CN Piperazine,

1-[[2-(4-chlorophenyl)ethenyl]sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidiny]carbonyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 179050-30-7 CAPLUS


CN Piperazine,

1-[(4'-bromo[1,1'-biphenyl]-4-yl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-31-8 CAPLUS

CN Piperazine, 1-[(3',5'-dichloro[1,1'-biphenyl]-4-yl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-34-1 CAPLUS

CN Piperazine, 1-[[4-(2-chlorophenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-2-chlorophenyl]piperazine (9CI) (CA INDEX NAME)




RN 179050-40-9 CAPLUS

CN Piperazine, 1-[[4-(2-iodophenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-2-iodophenyl]piperazine (9CI) (CA INDEX NAME)



RN 179050-42-1 CAPLUS

CN 2-Piperazinecarboxylic acid, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 179050-46-5 CAPLUS

CN Piperazine, 1-[(2-chloro-6-naphthalenyl)sulfonyl]-2-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]-2-[(1-(4-pyridinyl)-4-piperidinyl)carbonyl]piperazine (9CI) (CA INDEX NAME)

09/ 582,442


pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 179050-48-7 CAPLUS


CN Piperazine,

1-[(6-chloro-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 179050-49-8 CAPLUS


CN Piperazine, 1-[[1-(2-amino-4-pyrimidinyl)-4-piperidinyl]carbonyl]-4-[(6-chloro-2-naphthalenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 188526-29-6 CAPLUS


CN Piperazine,

1-[(4-fluoro-3,5-dimethylphenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 188526-30-9 CAPLUS


CN Piperazine, 1-[(4-fluorophenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-31-0 CAPLUS

CN Piperazine, 1-[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)


PAGE 1-A






RN 188526-32-1 CAPLUS

CN Piperazine, 1-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-4-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 188526-33-2 CAPLUS

CN Piperazine, 1-[(2-nitrophenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-34-3 CAPLUS

CN Piperazine, 1-(phenylsulfonyl)-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-35-4 CAPLUS

CN Piperazine, 1-[(5-chloro-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-36-5 CAPLUS

CN Piperazine, 1-[(3-bromophenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-38-7 CAPLUS

CN Piperazine, 1-(phenylmethyl)-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-41-2 CAPLUS

CN Piperazine, 1-[(4-cyanophenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-42-3 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)methyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-43-4 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[[1-(2-methyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-44-5 CAPLUS

CN Piperazine, 1-(phenylmethyl)-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-45-6 CAPLUS

CN Piperazine, 1-[(4-cyanophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-46-7 CAPLUS

CN Piperazine, 1-[(2-chloro-4-cyanophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-47-8 CAPLUS

CN Piperazine, 1-[(3,4-dichlorophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-48-9 CAPLUS

CN Piperazine, 1-[(4-methoxyphenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-49-0 CAPLUS

CN Piperazine, 1-[(4-chlorophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-50-3 CAPLUS

CN Piperazine, 1-[(2-cyanophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-51-4 CAPLUS

CN Piperazine, 1-[(2,4-difluorophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-52-5 CAPLUS

CN Piperazine, 1-[(4-butoxyphenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-53-6 CAPLUS

CN Piperazine, 1-[[4-(1,1-dimethylethyl)phenyl]sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-54-7 CAPLUS

CN Piperazine, 1-[[4-(1-methylethyl)phenyl]sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-55-8 CAPLUS

CN Piperazine, 1-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]-4-(2-thienylsulfonyl)- (9CI) (CA INDEX NAME)




RN 188526-56-9 CAPLUS

CN Piperazine, 1-[(5-chloro-2-thienyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-57-0 CAPLUS

CN Piperazine, 1-[(2,5-dichloro-3-thienyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-58-1 CAPLUS

CN Piperazine, 1-[(5-bromo-2-thienyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-59-2 CAPLUS

CN Piperazine, 1-[(4,5-dibromo-2-thienyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-60-5 CAPLUS

CN Piperazine, 1-[(4,5-dichloro-2-thienyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-61-6 CAPLUS

CN Piperazine, 1-[(1-methyl-1H-imidazol-4-yl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 188526-62-7 CAPLUS


CN Piperazine, 1-[[5-(2-pyridinyl)-2-thienyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-63-8 CAPLUS

CN Piperazine, 1-[(3,5-dimethyl-4-isoxazolyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 188526-64-9 CAPLUS
 CN Piperazine, 1-(cyclohexylsulfonyl)-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-65-0 CAPLUS
 CN Piperazine, 1-[(4-fluoro-3,5-dimethylphenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-66-1 CAPLUS

CN Piperazine, 1-[(3,6-dibromo-2,5-difluorophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-67-2 CAPLUS

CN Piperazine, 1-[(4-iodophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-68-3 CAPLUS

CN Acetamide, N-[4-[[4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]-1-piperazinyl]sulfonyl]phenyl]- (9CI) (CA INDEX NAME)




RN 188526-69-4 CAPLUS

CN Piperazine, 1-(phenylsulfonyl)-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-70-7 CAPLUS

CN Piperazine, 1-[(4-ethylphenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-71-8 CAPLUS

CN Piperazine, 1-[(4-propylphenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-72-9 CAPLUS

CN Piperazine, 1-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]-4-[(2,2,2-trifluoroethyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 188526-73-0 CAPLUS

CN Piperazine, 1-(butylsulfonyl)-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-74-1 CAPLUS

CN Piperazine, 1-[(1-methylethyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-75-2 CAPLUS

CN Piperazine, 1-(methylsulfonyl)-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 188526-76-3 CAPLUS


CN Piperazine, 1-[(4-methylphenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 188526-77-4 CAPLUS


CN Piperazine, 1-[(2,5-dibromophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-

piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-78-5 CAPLUS

CN Piperazine, 1-[[3,5-bis(trifluoromethyl)phenyl]sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-79-6 CAPLUS

CN Piperazine, 1-[[4-nitrophenyl]sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-80-9 CAPLUS

CN Piperazine, 1-[[4-chloro-3-nitrophenyl]sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-81-0 CAPLUS

CN Benzoic acid, 2-[[4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]-1-piperazinyl]sulfonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 188526-82-1 CAPLUS

CN Piperazine, 1-[(3,4-dibromophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-83-2 CAPLUS

CN Piperazine, 1-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]-4-[(2,4,5-trichlorophenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 188526-84-3 CAPLUS


CN Piperazine, 1-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]-4-[(2,4,6-trimethylphenyl)sulfonyl]- (9CI) (CA INDEX NAME)



RN 188526-85-4 CAPLUS

CN Piperazine, 1-[(3,5-dichlorophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-


piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 188526-86-5 CAPLUS


CN Piperazine,

1-[(2-chloro-4-fluorophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-87-6 CAPLUS

CN Piperazine, 1-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]-4-[[4-(trifluoromethoxy)phenyl]sulfonyl]- (9CI) (CA INDEX NAME)




RN 188526-88-7 CAPLUS

CN Piperazine, 1-[[2-chloro-4-(trifluoromethyl)phenyl]sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-89-8 CAPLUS

CN 2-Piperazinecarboxylic acid, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)




RN 188526-93-4 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[[1-(5-chloro-4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 188526-95-6 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 188526-96-7 CAPLUS

CN Piperazine, 1-[(4-fluorophenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




IT 179051-10-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of (di)azinylcarbonyl(di)azines as oxidosqualene cyclase
inhibitors)

RN 179051-10-6 CAPLUS

CN 2-Piperazinecarboxylic acid, 1-(phenylmethyl)-4-[[1-(4-pyridinyl)-4-

piperidinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



L4 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2001 ACS

ACCESSION NUMBER: 1996:455760 CAPLUS

DOCUMENT NUMBER: 125:114690

TITLE: Preparation of aminoheterocyclic derivatives as antithrombotic or anticoagulant agents

INVENTOR(S): Faull, Alan Wellington; Mayo, Colette Marie; Preston, John; Stocker, Andrew

PATENT ASSIGNEE(S): Zeneca Limited, UK

SOURCE: PCT Int. Appl., 161 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:



PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9610022	A1	19960404	WO 1995-GB2285	19950925
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2197471	AA	19960404	CA 1995-2197471	19950925
AU 9535307	A1	19960419	AU 1995-35307	19950925
AU 696491	B2	19980910		
EP 783500	A1	19970716	EP 1995-932128	19950925
EP 783500	B1	19980722		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
BR 9509045	A	19970930	BR 1995-9045	19950925
CN 1164232	A	19971105	CN 1995-196337	19950925
JP 10506122	T2	19980616	JP 1995-511499	19950925
AT 168685	E	19980815	AT 1995-932128	19950925
HU 77769	A2	19980828	HU 1997-2052	19950925
ES 2119472	T3	19981001	ES 1995-932128	19950925
CZ 285370	B6	19990714	CZ 1997-893	19950925
ZA 9508085	A	19960424	ZA 1995-8085	19950926
NO 9701415	A	19970522	NO 1997-1415	19970325

US 5965559
PRIORITY APPLN. INFO.:

A 19991012

US 1997-817031 19970326
GB 1994-19341 19940926
GB 1994-25789 19941221
GB 1995-11051 19950601
WO 1995-GB2285 19950925

OTHER SOURCE(S): MARPAT 125:114690
GI



AB The title compds. [I; G1, G2, G3 = CH, N; m = 1, 2; R1 = H, halo, Cl-4 alkyl; M1 = (substituted) piperidino, piperazino, etc.; A = bond, Cl-4 alkylene; M2 = piperazino, etc.; M3 = bond, etc.; X = SO2; Q = naphthyl, heterocyclyl] were prepd. and formulated. Treatment of 1-(4-pyridyl)piperidine-4-carboxylic acid with SOCl2 followed by addn. of 1-tert-butoxycarbonylpiperazine, deprotection of the intermediate II (Y = Boc) with HCl/Et2O and reaction of piperazine II.3HCl (Y = H) with 2-naphthylsulfonyl chloride afforded I [G1, G2, G3 = CH; R1 = H; M1 = piperidino; A, M3 = bond; M2 = piperazino; X = SO2; Q = 2-naphthyl]. In general, compds. I showed IC50 of 0.001-25 .mu.M against Factor Xa and of > 50 .mu.M against thrombin.

IT 179050-42-1P

RL: BAC (Biological activity or effector, except adverse); RCT

(Reactant);


SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of aminoheterocyclic derivs. as antithrombotic or anticoagulant agents)

RN 179050-42-1 CAPLUS

CN 2-Piperazinecarboxylic acid, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX

NAME)




IT 179049-56-0P 179049-65-1P 179049-81-1P
 179049-82-2P 179049-91-3P 179049-92-4P
 179049-93-5P 179049-94-6P 179049-95-7P
 179049-96-8P 179049-97-9P 179049-98-0P
 179049-99-1P 179050-00-1P 179050-01-2P
 179050-02-3P 179050-03-4P 179050-04-5P
 179050-05-6P 179050-06-7P 179050-07-8P
 179050-08-9P 179050-09-0P 179050-10-3P
 179050-11-4P 179050-12-5P 179050-13-6P
 179050-14-7P 179050-15-8P 179050-17-0P
 179050-22-7P 179050-23-8P 179050-24-9P
 179050-25-0P 179050-26-1P 179050-27-2P
 179050-28-3P 179050-29-4P 179050-30-7P
 179050-31-8P 179050-32-9P 179050-33-0P
 179050-34-1P 179050-35-2P 179050-36-3P
 179050-37-4P 179050-38-5P 179050-39-6P
 179050-40-9P 179050-41-0P 179050-43-2P
 179050-44-3P 179050-45-4P 179050-46-5P
 179050-48-7P 179050-49-8P 179050-50-1P
 179050-51-2P 179050-56-7P 179050-58-9P
 179050-59-0P 179050-60-3P 179050-61-4P
 179050-62-5P 179050-63-6P 179050-65-8P
 179050-66-9P 179050-69-2P 179051-81-1P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of aminoheterocyclic derivs. as antithrombotic or anticoagulant agents)

RN 179049-56-0 CAPLUS


CN Piperazine, 1-(2-naphthalenylsulfonyl)-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




09/ 582,442

RN 179049-65-1 CAPLUS
CN Piperazine, 1-(1-naphthalenylsulfonyl)-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)


PAGE 1-A



PAGE 2-A




RN 179049-81-1 CAPLUS
CN Piperazine, 1-[(8-chloro-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179049-82-2 CAPLUS

CN 2-Piperazinecarboxylic acid, 1-(2-naphthalenylsulfonyl)-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 179049-91-3 CAPLUS


CN Piperazine, 1-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-4-[[5-(2-pyridinyl)-2-thienyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 179049-92-4 CAPLUS


CN Piperazine, 1-[[2-(4-chlorophenyl)ethenyl]sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 179049-93-5 CAPLUS
 CN Piperazine,
 1-[[2-(4-methylphenyl)ethenyl]sulfonyl]-4-[[1-(4-pyridinyl)-4-
 piperidinyl]carbonyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 179049-94-6 CAPLUS
 CN Piperazine,
 1-[[2-(2-methylphenyl)ethenyl]sulfonyl]-4-[[1-(4-pyridinyl)-4-
 piperidinyl]carbonyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 179049-95-7 CAPLUS
 CN Piperazine,
 1-[[2-(4-fluorophenyl)ethenyl]sulfonyl]-4-[[1-(4-pyridinyl)-4-
 piperidinyl]carbonyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 179049-96-8 CAPLUS

CN Piperazine,

1-[[2-(2-chlorophenyl)ethenyl]sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 179049-97-9 CAPLUS

CN Piperazine,

1-[[2-(3-chlorophenyl)ethenyl]sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 179049-98-0 CAPLUS

CN Piperazine, 1-[[2-(3,4-dichlorophenyl)ethenyl]sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 179049-99-1 CAPLUS

CN Piperazine, 1-[[2-(4-bromophenyl)ethenyl]sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidiny]carbonyl]-, (E)- (9CI) (CA INDEX NAME)


Double bond geometry as shown.



RN 179050-00-1 CAPLUS


CN Piperazine, 1-[[1-(4-pyridinyl)-4-piperidiny]carbonyl]-4-[[2-[4-(trifluoromethyl)phenyl]ethenyl]sulfonyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




RN 179050-01-2 CAPLUS

CN Piperazine, 1-[[4-chloro-2-naphthalenyl]sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-02-3 CAPLUS

CN Piperazine, 1-[(7-chloro-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-03-4 CAPLUS

CN Piperazine, 1-[(7-ethoxy-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-04-5 CAPLUS

CN Piperazine, 1-[(6,7-dimethoxy-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-05-6 CAPLUS

CN Piperazine, 1-[(6-chloro-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-06-7 CAPLUS

CN Piperazine, 1-[(6-bromo-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-07-8 CAPLUS

CN Piperazine, 1-[(6-methoxy-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-08-9 CAPLUS

CN Piperazine, 1-[(7-methoxy-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-09-0 CAPLUS

CN Piperazine, 1-[(6-fluoro-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-10-3 CAPLUS

CN Piperazine, 1-[(4-bromophenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-11-4 CAPLUS

CN Piperazine, 1-([1,1'-biphenyl]-4-ylsulfonyl)-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-12-5 CAPLUS

CN Piperazine, 1-[(4'-chloro[1,1'-biphenyl]-4-yl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-13-6 CAPLUS

CN Piperazine, 1-(3-dibenzofuranylsulfonyl)-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-14-7 CAPLUS

CN 2-Piperazinecarboxylic acid, 1-(2-naphthalenylsulfonyl)-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-15-8 CAPLUS

CN 2-Piperazinecarboxylic acid, 4-(2-naphthalenylsulfonyl)-1-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 179050-17-0 CAPLUS


CN Piperazinone, 1-(2-naphthalenylmethyl)-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 179050-22-7 CAPLUS


CN Piperazine, 2,5-dimethyl-1-(2-naphthalenylsulfonyl)-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-, trans- (9CI) (CA INDEX NAME)

Relative stereochemistry.




RN 179050-23-8 CAPLUS

CN Piperazine, 2-methyl-4-(2-naphthalenylsulfonyl)-1-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 179050-24-9 CAPLUS


CN Piperazine, 2-methyl-1-(2-naphthalenylsulfonyl)-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 179050-25-0 CAPLUS


CN Piperazine, 4-[[2-(4-chlorophenyl)ethenyl]sulfonyl]-2-methyl-1-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 179050-26-1 CAPLUS


CN Piperazine, 1-(2-naphthalenylsulfonyl)-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]-2-methyl-4-[[2-(4-chlorophenyl)ethenyl]sulfonyl]- (E)- (9CI) (CA INDEX NAME)



RN 179050-27-2 CAPLUS

CN Piperazine,

1-[[1-(2-amino-6-methyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]-
4-(2-naphthalenylsulfonyl)- (9CI) (CA INDEX NAME)




RN 179050-28-3 CAPLUS

CN Piperazine,


1-[[2-(4-chlorophenyl)ethenyl]sulfonyl]-4-[[1-(4-pyrimidinyl)-
4-piperidinyl]carbonyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 179050-29-4 CAPLUS


CN Piperazine, 1-[(4'-methyl[1,1'-biphenyl]-4-yl)sulfonyl]-4-[[1-(4-
pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 179050-30-7 CAPLUS


CN Piperazine,

1-[(4'-bromo[1,1'-biphenyl]-4-yl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-31-8 CAPLUS

CN Piperazine, 1-[(3',5'-dichloro[1,1'-biphenyl]-4-yl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-32-9 CAPLUS

CN Piperazine, 1-[(4'-chloro[1,1'-biphenyl]-3-yl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-33-0 CAPLUS

CN Piperazine, 1-([1,1'-biphenyl]-3-ylsulfonyl)-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-34-1 CAPLUS

CN Piperazine, 1-[(4-iodophenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-35-2 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[[4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-1-piperazinyl]sulfonyl]-, ethyl ester (9CI) (CA INDEX NAME)




RN 179050-36-3 CAPLUS

CN Piperazine, 1-[(4'-cyano[1,1'-biphenyl]-4-yl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 179050-37-4 CAPLUS


CN Piperazine, 1-[(3',5'-dichloro[1,1'-biphenyl]-3-yl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 179050-38-5 CAPLUS

CN Piperazine,


1-[(4'-nitro[1,1'-biphenyl]-4-yl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)



RN 179050-39-6 CAPLUS


CN Piperazine,

1-[(4'-chloro-2'-nitro[1,1'-biphenyl]-4-yl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-40-9 CAPLUS


CN Piperazine, 1-[[4-(2-pyridinyl)phenyl]sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidiny]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-41-0 CAPLUS
 CN 2-Piperazinecarboxylic acid, 4-(2-naphthalenylsulfonyl)-1-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-43-2 CAPLUS
 CN 2-Piperazinecarboxylic acid, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 179050-44-3 CAPLUS
 CN Piperazine,
 4-(2-naphthalenylsulfonyl)-2-(1-piperidinylcarbonyl)-1-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-45-4 CAPLUS
 CN Piperazine,
 1-(2-naphthalenylsulfonyl)-2-(1-piperidinylcarbonyl)-4-[[1-(4-pyridinyl)-1-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 179050-46-5 CAPLUS


CN Piperazine, 1-(2-naphthalenylsulfonyl)-2-(phenylmethyl)-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 179050-48-7 CAPLUS


CN Piperazine,

1-[(6-chloro-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyrimidinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-49-8 CAPLUS

CN Piperazine, 1-[[1-(2-amino-4-pyrimidinyl)-4-piperidinyl]carbonyl]-4-[(6-chloro-2-naphthalenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 179050-50-1 CAPLUS

CN Piperazine, 1-[(6-chloro-2-naphthalenyl)sulfonyl]-4-[[1-(5,6-dichloro-4-pyridazinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-51-2 CAPLUS

CN Piperazine,
1-[(6-chloro-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyridazinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-56-7 CAPLUS

CN 2-Piperazinemethanol, 4-(2-naphthalenylsulfonyl)-1-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)




RN 179050-58-9 CAPLUS

CN [1,1'-Biphenyl]-4-carboxylic acid, 4'-[[4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-1-piperazinyl]sulfonyl]- (9CI) (CA INDEX NAME)



RN 179050-59-0 CAPLUS


CN Piperazine, 1-[(6-hydroxy-2-naphthalenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-, sodium salt (9CI) (CA INDEX NAME)



● Na

RN 179050-60-3 CAPLUS


CN 2-Piperazineacetic acid,
1-(2-naphthalenylsulfonyl)-4-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 179050-61-4 CAPLUS

CN 2-Piperazinecarboxylic acid,


4-[(6-bromo-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



RN 179050-62-5 CAPLUS

CN 2-Piperazinecarboxylic acid,


4-[(6-bromo-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 179050-63-6 CAPLUS

CN Morpholine,


4-[[4-[(6-bromo-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-2-piperazinyl]carbonyl]- (9CI) (CA INDEX NAME)



RN 179050-65-8 CAPLUS


CN Piperazine,

1-[[1-(2-amino-6-methyl-4-pyrimidinyl)-4-piperidinyl]carbonyl]-
4-[(6-chloro-2-naphthalenyl)sulfonyl]- (9CI) (CA INDEX NAME)




RN 179050-66-9 CAPLUS

CN 2-Piperazinecarboxylic acid, 4-[(6-chloro-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 179050-69-2 CAPLUS


CN Glycine, N-[[4-[(6-bromo-2-naphthalenyl)sulfonyl]-1-[[1-(4-pyridinyl)-4-piperidinyl]carbonyl]-2-piperazinyl]carbonyl]-, methyl ester (9CI) (CA INDEX NAME)



RN 179051-81-1 CAPLUS

CN Piperazine, 1-[(2-phenylethenyl)sulfonyl]-4-[[1-(4-pyridinyl)-4-piperidiny]carbonyl]-, (E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.




IT 179051-10-6P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
(prepn. of aminoheterocyclic derivs. as antithrombotic or
anticoagulant agents)

RN 179051-10-6 CAPLUS

CN 2-Piperazinecarboxylic acid, 1-(phenylmethyl)-4-[[1-(4-pyridinyl)-4-piperidiny]carbonyl]-, ethyl ester (9CI) (CA INDEX NAME)



=> d his

09/ 582,442

(FILE 'HOME' ENTERED AT 10:05:32 ON 09 JAN 2001)

FILE 'REGISTRY' ENTERED AT 10:05:38 ON 09 JAN 2001

L1 STRUCTURE UPLOADED
L2 18 S L1
L3 375 S L1 FUL

FILE 'CAPLUS' ENTERED AT 10:06:53 ON 09 JAN 2001

L4 8 S L3

=> log y

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	36.12	170.14
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE	-4.70	-4.70

STN INTERNATIONAL LOGOFF AT 10:11:31 ON 09 JAN 2001